How Catamaran Corp (CTRX) Impressed Wall Street This Quarter

NEW YORK (TheStreet) -- Catamaran Corp (CTRX) stock is surging on Thursday after the managed healthcare provider reported better-than-expected earnings and revenue in its first quarter. 

By midafternoon, shares had spiked 11.7% to $42.16.

In its March-ending quarter, Schaumburg, Ill.-based Catamaran reported net income of 50 cents a share, 6 cents higher than analysts' estimates according to Thomson Reuters surveys. Revenue soared 52.2% year over year to $4.9 billion. Analysts expected $4.69 billion in revenue. 

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates CATAMARAN COP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate CATAMARAN CORP (CTRX) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself."

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing